Charles River Laboratories (NYSE: CRL) has completed its acquisition of HemaCare Corporation (OTCMKTS: HEMA) for $380 million in cash, or $25.40 per HemaCare share. [Read more…]
CAR-T Cell Therapy Attracts Vast Sums of Money
What is CAR-T therapy? Chimeric antigen receptor T-cell (CAR-T) therapy is a targeted approach to treating cancer that uses a patient’s T cells, which are a type of immune system cell.
Since the first CAR-T therapy approvals in 2017 by the U.S. FDA, CAR-T deal-making has attracted vast sums of money. This article summarizes recent partnerships and deal-making with the CAR-T marketplace. [Read more…]
GIOSTAR Chicago Launches GIOTalk – a New Healthcare Podcast
Program features discussions with key players in the healthcare industry
CHICAGO, Illinois, December 4, 2019 — GIOSTAR Chicago – a leader in regenerative technologies – is proud to introduce GIOTalk, a podcast focusing on stem cells and broader issues impacting the field of healthcare.
Hosted by renowned plastic surgeon Dr. Michael Gellis, GIOTalk features interviews with medical practitioners and researchers, along with patients looking to share their experiences with stem cell therapy. Through these discussions, GIOSTAR Chicago seeks to provide listeners with diverse perspectives on this dynamic industry. [Read more…]
How Celularity is Leading the Next Evolution in Cellular Medicine
Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta. Using proprietary technology in combination with its IMPACT™ platform, Celularity is the only company harnessing the purity and versatility of placental-derived cells to develop and manufacture innovative and highly scalable off-the-shelf treatments for patients with cancer, inflammatory and age-related diseases.
Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity is uniquely positioned to harness the potential of most biocreative event on earth: human birth. [Read more…]
Cesca Partners with Healthbank Biotech (Stem Cell Bank) to Provide Immune Cell Banking
ImmuneCyte to Begin Operations in Fourth Quarter of 2019
RANCHO CORDOVA, Calif., Oct. 22, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary, today announced that the company has entered into a definitive joint venture agreement with HealthBanks Biotech (USA) Inc., one of the world’s leading stem cell bank networks, to commercialize its proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO). The joint venture will be named ImmuneCyte Life Sciences Inc. (“ImmuneCyte”) and is expected to officially launch during the fourth quarter of 2019. [Read more…]
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 47
- Next Page »